you are here: HomeNewsBiocon
biocon
Jump to
1508 Results Found
  • Limited downside in Biocon: Mavani Jan 20, 2011 01:43 PM IST

    Limited downside in Biocon: Mavani

    Limited downside in Biocon, says Vivek Mavani, Vice President & Senior Portfolio Manager, Brics Securities.

  • Biocon Q3 cons net profiit rises 24.85% at Rs 101 cr Jan 20, 2011 10:42 AM IST

    Biocon Q3 cons net profiit rises 24.85% at Rs 101 cr

    Indian biotechnology firm Biocon has declared its results for the quarter ended December 2010. It has reported consolidated net profiit at Rs 101 crore as against Rs 80.9 crore, a growth of 24.85% on year-on-year basis.

  • Biocon Q3 profit after tax seen up 15% to Rs 93 cr Jan 20, 2011 07:36 AM IST

    Biocon Q3 profit after tax seen up 15% to Rs 93 cr

    Indian biotechnology firm Biocon is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax is expected go up by 15% to Rs 93 crore in Q3FY11 as against Rs 80.9 crore in same period of previous year.

  • Biocon: Oral insulin fails to meet primary target Jan 11, 2011 10:45 AM IST

    Biocon: Oral insulin fails to meet primary target

    Biocon on Tuesday said initial data from late-stage clinical trials on its experimental oral insulin drug for diabetes did not meet the desired results, but said it was committed to the global development of the drug.

  • Biocon can test Rs 445: Amit Gupta Jan 05, 2011 10:44 AM IST

    Biocon can test Rs 445: Amit Gupta

    Biocon can test Rs 445, says Amit Gupta of ICICI Securities.

  • Deal boost for Biocon Jan 04, 2011 09:35 AM IST

    Deal boost for Biocon

    The firm is looking at partnerships with global pharma majors as a ticket to hasten the launch of its biotech products

  • Kapadia positive on Biocon Jan 03, 2011 07:41 PM IST

    Kapadia positive on Biocon

    Ranjit Kapadia, Vice President-Institutional Research, HDFC Securities is positive on Biocon.

  • Clinigene & Syngene may list in a year's time: Biocon Jan 03, 2011 10:59 AM IST

    Clinigene & Syngene may list in a year's time: Biocon

    In an exclusive interview with CNBC-TV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene & Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 24-36 months.

Sections